Oncure Drugs Profile
Key Indicators
- Authorised Capital ₹ 0.10 M
as on 17-11-2024
- Paid Up Capital ₹ 0.10 M
as on 17-11-2024
- Company Age 4 Year, 2 Months
- Last Filing with ROC 31 Mar 2024
- Revenue %
(FY 2023)
- Profit 133.41%
(FY 2023)
- Ebitda -5.42%
(FY 2023)
- Net Worth 33.79%
(FY 2023)
- Total Assets 2.54%
(FY 2023)
About Oncure Drugs
The Company is engaged in the Pharma Industry.
The Company's status is Active, and it has filed its Annual Returns and Financial Statements up until 31 March 2024. It's a company limited by shares with an authorized capital of Rs 0.10 M and a paid-up capital of Rs 0.10 M, as per Ministry of Corporate Affairs (MCA) records.
Bhargavi Mehta, Ashit Mehta, and Harsh Mehta serve as directors at the Company.
- CIN/LLPIN
U24290MH2020PTC350724
- Company No.
350724
- Company Classification
Private Limited Indian Non-Government Company
- Incorporation Date
25 Nov 2020
- Date of AGM
30 Sep 2024
- Date of Balance Sheet
31 Mar 2024
- Listing Status
Unlisted
- ROC Code
Roc Mumbai
Industry
Company Details
- Location
Mumbai, Maharashtra, India
- Telephone
- Email Address
- Website
-
- Social Media-
Who are the key members and board of directors at Oncure Drugs?
Board Members (3)
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
Bhargavi Mehta  | Director | 25-Nov-2020 | Current |
| Ashit Mehta | Director | 25-Nov-2020 | Current |
| Harsh Mehta | Director | 25-Nov-2020 | Current |
Financial Performance of Oncure Drugs.
Oncure Drugs Private Limited, for the financial year ended 2023, experienced no change in revenue, with a 0% increase. The company also saw a substantial improvement in profitability, with a 133.41% increase in profit. The company's net worth Soared by an impressive increase of 33.79%.
- Key Matrics
- Balance Sheet
- Profit and Loss
- Cash Flow
- Ratios
| Metrics |
| (FY 2022) | (FY 2021) | (FY 2020) | (FY 2019) | ||
|---|---|---|---|---|---|---|---|
| Total Revenue | |||||||
| Revenue from Operations | |||||||
| Total Assets |
| ||||||
| Profit or Loss |
| ||||||
| Net Worth |
| ||||||
| EBITDA |
|
What is the Ownership and Shareholding Structure of Oncure Drugs?
Unlock access to Oncure Drugs's control and ownership data, Corporate Shareholding Patterns, Funding (security allotment) details, Foreign Institutional Investor information, Directors and Key Management Personnel (KMP) Remuneration, Group Structure, Overseas Direct Investment and other pertinent data.
Related Corporates (Common Directorship)
A-Star Dyes & Chemicals LlpActive 13 years 10 monthsBhargavi Mehta and Ashit Mehta are mutual person
- Mazda Healthclub Equipments LlpActive 3 years 9 months
Bhargavi Mehta and Harsh Mehta are mutual person
- Manan Cotsyn Private LimitedActive 17 years 9 months
Bhargavi Mehta and Ashit Mehta are mutual person
- Sunrise Auxichem Private LimitedActive 17 years 3 months
Bhargavi Mehta, Ashit Mehta and 1 more are mutual person
Charges (Loans)
There are no open charges registered against the company as per our records.
How Many Employees Work at Oncure Drugs?
Oncure Drugs has a workforce of 0 employees as of Apr 03, 2024. Unlock access to detailed historical data on individuals associated with the company, including employment records, contributions to the Employees' Provident Fund Organization (EPFO), and other related insights.
Deals i
Gain comprehensive insights into the Deals and Valuation data of Oncure Drugs, offering detailed information on various transactions, including security allotment data. Explore the intricate details of financial agreements, mergers, acquisitions, divestitures, and strategic partnerships that have shaped Oncure Drugs's trajectory.
Rating
Access the credit rating data, providing valuable insights into the company's creditworthiness and financial stability. Explore assessments from leading credit rating agencies, evaluating factors such as debt obligations, liquidity, profitability, and overall financial health.
Alerts
Stay informed about regulatory alerts and litigation involving and associated companies. Receive timely updates on legal proceedings, regulatory changes, and compliance issues that may impact the company's operations, reputation, and financial performance. Monitor litigation involving subsidiaries, joint ventures, and other affiliated entities to assess potential risks and liabilities.